Three Current Analyst Reports Recommend Nymox.

Business Editors/Health/Medical Writers

NEW YORK--(BUSINESS WIRE)--Oct. 16, 2003

Nymox (NASDAQ: NYMX) Now Rated "Buy" by Dutton and Company, "Buy" by Kareg Corporation, and "Speculative Buy" by WallStreet Research

Three independent analyst

reports recommend Nymox Pharmaceutical Corporation (NASDAQ: NYMX). The most recent "Buy" recommendation written on October 6, 2003, is from Dutton and Company, written by Sherry Grisewood, CFA. The "Buy" recommendation from Kareg Corporation was written by Sheldon S. Traube, Director of Research on June 16, 2003. The "Speculative Buy" from WallStreet Research was written by Alan Stone on June 19, 2003.

The new Dutton report states, "Nymox is pursuing a three-pronged strategy to address Alzheimer's disease: prevention, detection and diagnosis, and treatment. With the social and economic consequences of Alzheimer's disease (AD) looming over the medical profession as the world's population ages, advances in all three areas will be necessary. Prevention and diagnosis issues have taken on a new focus as researchers begin to unravel some of the mysteries of this disease. Nymox remains well positioned to address these needs, with the Company's current technology in AD-associated proteins and its patent for the use of statins as preventative and therapeutic measures against AD."

The report concludes "Further, with increased focus on statins and AD, amid a number of other AD therapeutic failures, it is becoming more realistic to view Nymox's patent on the use of statins in AD as a significant wildcard, which is not reflected in the current value of the Company. We are maintaining our rating of the shares as a Buy."

The WallStreet Research report states, "With no long-term debt and a low burn rate compared to industry standards, especially considering the number of marketed products and advanced projects in the pipeline, the Company appears to be an excellent buying opportunity for speculative investors." The report also states "The shares could immediately become more valuable upon announcement of significant milestones, such as meaningful marketing or other alliances."

According to the Kareg report, "With two products already being offered commercially serving large potential markets; proprietary platforms allowing for development of unique additional drugs and diagnostic tests; seasoned management and Board of Directors; a low burn rate; an improved financial position with no long-term debt; some recent equity financing; and past ability to raise capital with little dilution (an average of 4.2% annually over the past four years); we recommend purchase of the NYMX shares."

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

The above analyst reports contain disclaimers stated in each individual report, and also stated in Nymox's initial press releases on the issuance of the reports, which concern risks, uncertainties, and limitations of the reports. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.